---
document_datetime: 2023-09-21 21:15:04
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zynquista-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: zynquista-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5040331
conversion_datetime: 2025-12-28 10:40:57.589221
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zynquista (SRD)

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                       | Opinion/ Notification 1 issued on Product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|-------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| PSUSA/10766 /202104  | Periodic Safety Update EU Single assessment - sotagliflozin | 02/12/2021                                  | n/a                                         |                                  | PRAC Recommendation - maintenance |
| PSUSA/10766 /202010  | Periodic Safety Update EU Single assessment - sotagliflozin | 10/06/2021                                  | n/a                                         |                                  | PRAC Recommendation - maintenance |

<!-- image -->

Medicinal Product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

| PSUSA/10766 /202004   | Periodic Safety Update EU Single assessment - sotagliflozin                                                                                                                                                  | 26/11/2020   | n/a                                | PRAC Recommendation - maintenance   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------------------------------|-------------------------------------|
| IAIN/0005             | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                   | 24/09/2020   | 24/01/2022 SmPC, Labelling and     |                                     |
| PSUSA/10766 /201910   | Periodic Safety Update EU Single assessment - sotagliflozin                                                                                                                                                  | 14/05/2020   | n/a                                | PRAC Recommendation - maintenance   |
| T/0002                | Transfer of Marketing Authorisation                                                                                                                                                                          | 18/12/2019   | 23/01/2020 Labelling and PL longer | SmPC,                               |
| IB/0001               | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 05/08/2019   | n/a no                             |                                     |

Medicinal Product no longer authorised